Chronic Pain News and Research

RSS

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company is pleased to announce that the company has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.

31 Aug 2009

DURECT signs agreement with King Pharmaceuticals to supply two excipients for REMOXY

DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under which DURECT will supply to King, based on DURECT's manufacturing cost plus a specified percentage mark-up, two key excipients used in the manufacture of REMOXY.

27 Aug 2009

Canadian Anesthesiologists' Society responds to reports on Michael Jackson's death

The Canadian Anesthesiologists' Society (CAS) represents the only trained physicians providing anesthetic services in Canada. CAS is responding to reports that Michael Jackson was given a fatal combination of drugs, including the powerful anesthetic propofol, prior to his death on June 25.

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Study confirms inappropriate use of pain medication among the chronic pain population

A study published in the August issue of the peer-reviewed journal Population Health Management revealed that the majority of patients prescribed opioids for chronic pain were unlikely to be taking their medicine in a manner consistent with their prescribed regimen. In the study, titled "Inappropriate Drug Use in the Chronic Pain Population," 938,586 urine toxicology tests conducted on over 500,000 patients prescribed chronic opioid therapy were analyzed using proprietary and state of the art screening methods offered by Ameritox(R).

27 Aug 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Medication safety program on safe prescribing procedures for narcotic drugs launched

Warnings by the Food and Drug Administration (FDA) and increasing misuse and overdoses are telling reminders of the dangers pain medications can present. A recent study reveals that one in 10 high school students have tried opioid drugs and the prevalence of young adults using narcotics for non-medical use is the highest in 15 years.

20 Aug 2009

Cognitive behavioral therapy improves sleep and pain in osteoarthritis

A study in the Aug. 15 issue of the Journal of Clinical Sleep Medicine shows that the use of cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for older patients with osteoarthritis and comorbid insomnia.

16 Aug 2009

Endocannabinoids found to spread and prolong pain

Imagine that you're working on your back porch, hammering in a nail. Suddenly you slip and hit your thumb instead - hard. The pain is incredibly intense, but it only lasts a moment. After a few seconds (and a few unprintable words) you're ready to start hammering again.

13 Aug 2009

Massage therapy eases sickle cell disease pain in children

Massage offers both physical and psychological benefits and is used at Nationwide Children’s Hospital in many areas including Rehabilitation, Physical Medicine and in patients who have received organ transplants, just to name a few. Researchers at Nationwide Children’s recently published a study in the Journal of Pediatric Psychology that revealed the benefits of massage in reducing pain, anxiety and depression in children with Sickle Cell Disease.

12 Aug 2009

Traditional Chinese acupuncture affects the brain's long-term ability to regulate pain

Acupuncture has been used in East-Asian medicine for thousands of years to treat pain, possibly by activating the body's natural painkillers. But how it works at the cellular level is largely unknown.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Transcranial MR-guided focused ultrasound for brain disorders a step closer

A team of researchers working at the MR-Center of the University Children's Hospital in Zürich has completed a pilot study using transcranial MR-guided focused ultrasound to treat 10 patients with neuropathic pain.

9 Aug 2009

Watson recalls one lot of Fentanyl transdermal system

Watson Pharmaceuticals has announced that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

9 Aug 2009

Compound from coral offers hope fpr neuropathic pain

A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system.

4 Aug 2009

Depression and inflammation linked to rheumatoid arthritis pain

Researchers at Nagoya City University and Nagoya University Graduate Schools of Medicine in Japan studied the interrelationship between levels of depression symptoms, C-reactive protein (CRP) level, and pain, confirming a significant positive association between depressive symptoms and CRP level in RA.

4 Aug 2009

Chronic Pain News and Research

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

DURECT signs agreement with King Pharmaceuticals to supply two excipients for REMOXY

Canadian Anesthesiologists' Society responds to reports on Michael Jackson's death

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Study confirms inappropriate use of pain medication among the chronic pain population

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Study reveals that increased neurostimulation market offers growth for device industries

Nutra Pharma launches Cobroxin for chronic pain relief

Medication safety program on safe prescribing procedures for narcotic drugs launched

Cognitive behavioral therapy improves sleep and pain in osteoarthritis

Endocannabinoids found to spread and prolong pain

Massage therapy eases sickle cell disease pain in children

Traditional Chinese acupuncture affects the brain's long-term ability to regulate pain

Array Biopharma reports Q4 and full year 2009 financials

Transcranial MR-guided focused ultrasound for brain disorders a step closer

Watson recalls one lot of Fentanyl transdermal system

Compound from coral offers hope fpr neuropathic pain

Depression and inflammation linked to rheumatoid arthritis pain

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News